Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial
LANCET HAEMATOLOGY
Greil, R; Obrtlikova, P; Smolej, L; Kozak, T; Steurer, M; Andel, J; Burgstaller, S; Mikuskova, E; Gercheva, L; Nosslinger, T; Papajik, T; Ladicka, M; Girschikofsky, M; Hrubisko, M; Jager, U; Fridrik, M; Pecherstorfer, M; Kralikova, E; Burcoveanu, C; Spasov, E; Petzer, A; Mihaylov, G; Raynov, J; Oexle, H; Zabernigg, A; Flochova, E; Palasthy, S; Stehlikova, O; Doubek, M; Altenhofer, P; Pleyer, L; Melchardt, T; Klingler, A; Mayer, J; Egle, A, 2016: Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. LANCET HAEMATOLOGY 3(7), p. E317 - E329, doi: 10.1016/S2352-3026(16)30045-X
CEITEC authors: